Pemigatinib approved in the EU for bile duct cancer

Pemigatinib, a kinase inhibitor, was granted conditional authorisation for locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, that have progressed after at least one prior line of systemic therapy.

Source:

PharmaTimes